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Surgical intervention for thoracic outlet syndrome
improves patient’s quality of life
David C. Chang, PhD, MPH, MBA, Lisa A. Rotellini-Coltvet, MA, MMS, PA-C,
Debraj Mukherjee, MD, MPH, Ricardo De Leon, MD, and Julie A. Freischlag, MD, Baltimore, Md
Objective: To assess long-term quality of life outcomes in patients following transaxillary first-rib resection and
scalenectomy for thoracic outlet syndrome (TOS).
Methods: This was a prospective observational study using the Short-Form 12 (SF-12) and Disability of Arm, Hand, and
Shoulder (DASH) instruments between February 2005 andMarch 2008 in patients with TOS presenting to an academic
medical center for preoperative surgical evaluation after failing physical therapy protocol. Surveys were conducted
preoperatively and then again at 3, 6, 12, 18, and 24months after surgery. Longitudinal data analysis was performedwith
population-averaged models using generalized estimating equations (GEE) method for average rate of recovery.
Kaplan-Meier method was used to analyze time to return to work.
Results: A total of 70 out of 105 eligible patients (66.7%) completed the study protocol (44 neurogenic; 26 venous),
returning 243 valid SF-12 surveys (162 neurogenic; 81 venous) and 188 valid DASH surveys (124 neurogenic; 64
venous). Half (50%) of the neurogenic patients and 77% of the venous patients returned to full-time work or activity
within the study follow-up, with half of them doing so by 4 months and 75% of them by 5 months. There was no
statistically significant difference in return to work between the neurogenic or venous patients. Neurogenic patients had
baseline SF-12 Physical Component Scores (PCS) similar to chronic heart failure patients and were significantly worse
than venous patients (33.8 vs 43.6, P < .001). In contrast, no difference existed in Mental Component Scores (MCS)
(44.5 vs 43.5, P  .78). In follow-up, on average, PCS scores for neurogenic patients improved 0.24 points (P < .001)
and MCS scores improved 0.15 points per month (P  .01); while PCS scores for venous patients improved 0.40 points
(P  .004) and MCS scores improved 0.55 points per month (P < .001). Additionally, neurogenic patients had baseline
DASH scores that were similar to patients with rotator cuff tears, and they were also significantly worse than venous
patients (50.2 vs 25.0, P< .001). DASH scores, on average, also improved 0.85 points (P< .001) for neurogenic patients
and 0.81 points (P < .001) for venous patients per month.
Conclusion: The use of the SF-12 and DASH instruments in patients with TOS demonstrated significant improvement in
patients postoperatively. Venous TOS patients typically improved both physical and mental scores in shorter periods of
time than their neurogenic counterparts. Neurogenic and venous TOS patients returned to full-time work/activity within
the same length of time postoperatively. However, neurogenic patients required more secondary interventions. We
conclude that in appropriately selected patients with either neurogenic or venous TOS, surgical intervention can improve
their quality of life over time. (J Vasc Surg 2009;49:630-7.)
Clinical Relevance: Surgical intervention is associated with significant improvement in quality of life for TOS patients.
Venous TOS patients improved physical and mental function in shorter time than neurogenic counterparts. The majority
of patients were able to return to full-time work or activity by 6 months, while they continued to recover their quality of
life. There was no difference in time to return to work or activity between neurogenic and venous patients; however,
neurogenic patients required more secondary interventions. In appropriately selected patients with either neurogenic or
venous TOS, surgical intervention can improve their quality of life over time.Thoracic outlet syndrome (TOS) represents a constel-
lation of signs and symptoms of the upper limb caused by
compression of the neurovascular plexus at the upper tho-
racic aperture. Clinical features of TOS differ between the
neurogenic and venous forms of the syndrome, which
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630represent 95% and 2% of all TOS cases, respectively.1,2
Neurogenic TOS commonly presents in patients with a
history of neck trauma and with symptoms including neck
pain and occipital headaches, as well as pain, paresthesia,
and weakness of the upper extremity. In contrast, venous
TOS commonly presents in patients with a history of exces-
sive activity of the upper extremity and with symptoms
including pain, cyanosis, and swelling of the arm with
secondary paresthesia. Both forms of TOS tend to manifest
during active working years of life (20-50 years of age).3-5
While venous TOS may be confirmed by ultrasound
scan or venogram, no definitive diagnostic tests, including
nerve conduction studies, electromyography, or sensory
testing, have been validated for neurogenic TOS.6,7 Thus,
the diagnosis of TOS remains largely a clinical one, with
patients often being seen by numerous specialists and la-
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by a vascular surgeon.8,9 The same challenge exists in
evaluating the outcomes of these patients postoperatively.
To date, there is limited data in the literature on the
quality of life and functional outcome of these patients. The
objective of this study is to quantify the degree and charac-
teristics of TOS patient disability using validated patient-
reported quality of life instruments—with the Disability of
the Arm, Shoulder and Hand (DASH) and the Short-Form
12 (SF-12)—and to assess long-term quality of life out-
comes in patients following transaxillary first-rib resection
and scalenectomy for TOS. We chose the DASH as a
disease-specific measure focusing on the upper extremity
functions that we are primarily interested in. The DASH
was developed by the American Academy of Orthopaedic
Surgeons as an outcome tool to evaluate “upper extremity-
related symptoms and measure functional status at the level
of disability”.10,11 Concepts covered by the DASH include
symptoms (pain, weakness, stiffness, and tingling/numb-
ness), physical function (daily activities, house/yard chores,
shopping, errands, recreational activities, self-care, dress-
ing, eating, sexual activities, sleep, and sport/performing
arts), social function (family care occupation, socializing
with friends/family), and psychological function (self-
image). To complement the DASH, and as a measure of
validity, we chose the SF-12 as an adjunctive instrument to
measure the overall health status of our patients. The SF-12
is a recently-developed condensed version of the popular
SF-36 that was developed from the Medical Outcomes
Study in the early 1990s.12 We chose the SF-12 to decrease
patient response burden.
METHODS
With Institutional Review Board (IRB) approval, pa-
tients age 18 and older presenting to an academic medical
center TOSclinic between February 2005 and March 2008
were asked to participate following informed consent.
These had patients who failed physical therapy prior to their
referrals. All patients then underwent transaxillary first-rib
resection.
Preoperative patient demographics and postoperative
clinical outcomes, including time to return to work, were
abstracted from clinical records. Quality of life data were
gathered using a survey package created with Optical Mark
Reader (Gravic, Inc, Malvern, Pa) technology.13 These
computer-readable forms can be answered with any writing
instruments and marked with simple check marks. The
system can generate the database automatically after scan-
ning, without manual data entry. Understandability and
acceptability of the questionnaire instruments were assessed
by open discussion with the first 5 patients following survey
completion. These surveys were administered preopera-
tively and then again at 3, 6, 12, 18, and 24 months after
surgery.
In analysis, the Physical Component Score (PCS) and
Mental Component Score (MCS) on the SF-12 scale were
standardized and normalized to population data (mean, 50,
standard deviation [SD] 10). Means were compared topopulation norms with one-sample t tests. Reliability of the
survey package was assessed by internal consistency, by
calculation of Cronbach’s alpha of the SF-12 subscales, and
factor analysis with principal factor estimation, with and
without varimax rotation, on the SF-12 subscales. Validity
of the survey package was assessed by convergent validity
via simple regression to determine association between
SF scores and DASH. The rate of recovery was deter-
mined with population-averaged models using general-
ized estimating equations (GEE) method. Kaplan-Meier
method was used to analyze time to return to work.
Patients with bilateral TOS and had previous rib resec-
tion were excluded from this analysis to avoid confound-
ing of the second surgery with long-term outcomes
analysis. Data analysis was performed in Stata SE version
9.2 (College Station, Tex).
RESULTS
A total of 70 out of 105 eligible patients (66.7%)
completed the study protocol (44 neurogenic; 26 venous),
returning 188 valid DASH surveys (124 neurogenic; 64
venous) and 243 valid SF-12 surveys (162 neurogenic; 81
venous). The remaining patients were consented but have
either not been scheduled for surgery or have had surgery
but have yet to return any valid survey. There was no
statistically significant difference in baseline survey scores
captured at the time of consent at initial clinic visits be-
tween the 70 patients who participated thus far in our study
vs the other patients who have yet to participate (PCS
37.3 vs 37.9, MCS 44.1 vs 47.9, and DASH 41.9 vs
34.9, all P  ns).
Preoperative patient demographics. Among the
neurogenic patients (n  44), there were 35 women
(79.5%), with a mean age of 40.2 years, and 9 men (20.5%),
with a mean age of 34.8 years. Preoperatively, neurogenic
patients had been symptomatic for a median of 36 months
(mean, 67.7 months; range, 4 months to 45 years), and 27
(61%) of these patients had symptoms secondary to occu-
pations or activities that required repetitive motion, while
13 (30%) experienced symptoms as a result of an accident
(work related, motor vehicle, and/or head trauma). One
patient had symptoms as a result of both repetitive motion
and trauma. Twelve (27%) of neurogenic patients had
previous surgery, including cervical spine, shoulder, or
elbow. Preoperative treatment included generalized physi-
cal therapy (33, or 75%), TOS-specific physical therapy (20,
or 45%), and scalene blocks (28, or 64%, including 28 with
lidocaine and 17 with Botox). Twenty-seven (96%) of the
lidocaine blocks and 14 (82%) of the Botox blocks were
positive and relieved symptoms.
Among venous patients (n  26), there were 13
women (50.0%), with a mean age of 37.1 years, and 13
men, with a mean age of 31.2 years. They experienced
symptoms for a median of 4.5 months (mean, 10.4 months;
range, 0-72 months) prior to consultation. Ten (38%),
attributed their condition to chronic repetitive motion;
their occupations included painting, carpentry, mechanics,
and music composition or performance. Acute effort
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population. These patients were active as quarterbacks,
pitchers, swimmers, and runners. Few (3, or 12%) had
trauma to or surgery on the affected arm, which was quite
different than the neurogenic patients.
Preoperative treatments for the venous population in-
cluded venography with clot lysis (13/26, or 50%) and
placement on anticoagulation (18/26, or 69%). None had
stent placement, and none had undergone physical therapy
or scalene blocks prior to the operation.
Postoperative clinical outcomes. Complication rates
in both neurogenic and venous TOS patient groups were
similar. Pneumothorax developed in 7 neurogenic patients
and 4 venous patients (11/70, 16%). These patients who
developed pneumothorax were identified by a tear in the
pleura at the time of surgery. A #12 chest tube was inserted
through the second intercostal space, attached to suction,
and later placed to water seal, and removed the next day.
Other complications included two wound infections and
one chest wall hematoma. No long thoracic nerve palsy or
brachial plexus injury was noted in any patient.
Physical therapy for 2 months was the initial postoper-
ative treatment for all patients undergoing a first-rib resec-
tion with scalenectomy. We give each patient instructions
for a TOS-specific physical therapy protocol. Neurogenic
patients required a median of 4 months (range, 1-18
months) of physical therapy, whereas the venous patients
required less, a median of 2 months (0-12 months), before
they felt symptom-free. All 26 venous TOS patients under-
went a 2-week postoperative venogram and required dila-
tation. Anticoagulation was administered to 18 venous
patients, 2 of whom required lifelong anticoagulation sec-
ondary to a hypercoagulable disorder, while the other 16
required a median of 3.5 months (0.5-11 months) follow-
ing surgery and venous dilatation.
Secondary intervention for recurrent symptoms during
the follow-up period included additional physical therapy,
Botox injections for chemodenervation, and muscle relax-
ation in the residual scalene anticus muscle, pectoralis ma-
jor, trapezius, or the rhomboids, and/or pain management
referral. Neurogenic TOS patients, on average, required
more secondary interventions than venous TOS patients.
Nine (20%) neurogenic patients required additional physi-
cal therapy starting at a median of 3.5 months (range, 0-18
months) postoperatively and lasting for a median of 2
months (range, 0-13 months). Only 5 (19%) venous pa-
tients required additional physical therapy, starting at a
median of 12 months postoperatively and lasting for a
median of 10 weeks. Eight (18%) neurogenic patients
required Botox injections at 1 year postoperatively for
chemodenervation and muscle relaxation; whereas only 1
(4%) venous patient required Botox injection. While no
venous patients needed pain management referral, 9 (20%)
of the neurogenic group were referred for this intervention
in the postoperative period over the first year.
Return to work. While 15/44 (34%) of neurogenic
patients and 2/26 (8%) of venous patients were disabled or
unemployed upon presentation, 22 (50%) neurogenic pa-tients and 20 (77%) venous patients eventually returned to
full-time work or activity at some time during the study
follow-up period. Activity was determined for patients who
were not employed at baseline, to account for athletes,
college students, musicians, and homemakers. This in-
cluded 3 of the 15 neurogenic patients and 1 of the 2
venous patients who were initially unemployed at baseline.
Additionally, there were 2 neurogenic patients and 2 ve-
nous patients who returned only to part-time activity.
The time course of returning to full-time work or
activity is presented in Fig 1. Half of the patients returned
to full-time work or activity by 4 months, and more than
75% returned by 5 months. There was no statistically sig-
nificant difference in return to work between neurogenic
and venous patients.
Quality of life outcome. Initial exploratory analysis
confirmed significant association between the SF-12 and
DASH instruments. Both the PCS and the MCS of the
SF-12 had significant association with the DASH, with
linear regression coefficients of 2.14 and 1.06, respec-
tively (both P  .001) (ie, 1 PCS point equals 2.14
DASH points, and 1 MCS point equals 1.06 DASH
points). Note that the direction of the scaling is opposite in
the SF-12 vs the DASH: whereas higher scores represent
better patient status on the SF-12, higher scores on the
DASH represent worse patient status. Additional simple
regression analyses revealed significant associations be-
tween DASH and all eight of the SF-12 subscales. Cron-
bach’s alpha of all SF-12 subscales was 0.87; Cronbach’s
alpha of only the four PCS-related subscales was 0.75, while
Cronbach’s alpha of only the four MCS-related subscales
was 0.83.
Separating neurogenic and venous TOS patient data on
baseline, it was found that neurogenic TOS patients had
significantly worse PCS values than venous TOS patients
(33.8 vs 43.6, P .001). In contrast, no difference existed
in their MCS values (44.5 vs 43.5, P  ns). The DASH
Fig 1. Proportion of patients returning to full-time work or ac-
tivity over time.scores were also significantly worse among neurogenic TOS
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.001).
In follow-up, on average, PCS scores for neurogenic
patients improved 0.24 points (P  .001) and MCS scores
improved 0.15 points per month (P .01) (Fig 2, a). PCS
scores for venous patients improved 0.40 points (P .004)
and MCS scores improved 0.55 points per month (P 
.001) on average in follow-up (Fig 2, b). DASH scores, on
average, also improved 0.85 points (P  .001) for neuro-
genic patients and 0.81 points (P  .001) for venous
patients per month.
Additionally, it was determined that for neurogenic
patients the median time to recovery of normal quality of
life was 23 months for physical function and 12 months for
mental function. In contrast, for venous TOS patients the
median time to recovery of normal quality of life was 11
months for physical function and 8 months for mental
function. Note that these recovery times were signifi-
cantly longer than the patients’ return to full-time work
or activity.
DISCUSSION
While some risk factors for persistent postoperative
Fig 2. Quality of life outcome of neurogenic TOS pat
(a2) Mental Component Scores (MCS); and venous TO
and (b2) Mental Component Scores (MCS).disability in TOS have been identified, measurement oflong-term postoperative mental and physical functional
outcomes has been lacking.14-16 Since corrective surgery
for TOS has demonstrated low rates of complication, anal-
ysis of long-term functional outcomes in TOS patients may
provide useful additional insight into the postoperative
course of patients.17,18 There have also been some attempts
to assess long-term outcomes, these efforts have primarily
focused on diffuse measures of patient satisfaction using
unvalidated tools.19-22 A recent report by Cordobes-Gual
et al23 presented some functional data using the validated
DASH instrument on 23 patients, but they included only a
single follow-up at approximately 4 to 6 months after
surgery.
In contrast to the limited studies in the literature, our
current study presents functional data on a larger subset of
patients (n 62) followed over a longer period of time (up
to 2 years) using objective and well-established quality of
life instruments. The findings of this study suggest that
despite the seemingly nebulous nature of their complaints,
these patients suffer striking physical morbidity from TOS.
The mean PCS of 37.5 on baseline was approximately 1.3
SDs below the population norm. This score is much worse
than the mean score of 46.4 that has been reported for
with their (a1) Physical Component Scores (PCS) and
ents, with their (b1) Physical Component Scores (PCS)ients,
S patichronic prostatitis patients, 46.5 for hypertension patients,
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the mean score of 34.0 that has been reported for chronic
heart failure patients.24-26 Similarly, the mean DASH score
of 41.4 is similar to the mean value of 43.7 that has been
reported for patients with chronic rotator cuff tears.27 The
validity of TOS patients’ physical complaints is further
supported by their MCS being within one SD of population
norm. Of note, the reported MCS on the SF-12 are also
similar between TOS patients on baseline in this study
(43.7) vs chronic heart failure patients (48.2).26
We observed significant differences between recovery
to full-time work or activity vs recovery to normal quality of
life scores. Half of patients were able to return to full-time
work or activity by 3 months and 75% were able to do so by
6 months, in contrast to the 1-2 years of recovery time until
quality of life scores normalized. This suggests that patients
can return to full-time work or activity while they continue
to recover. This can be an important point in patient
counseling on expected recovery course.
This study has multiple strengths. We specifically as-
sessed and confirmed the reliability and validity of using the
SF-12 for a study on TOS patients. The reliability, as
assessed by internal consistency, was demonstrated by the
high Cronbach’s alpha of eight SF-12 subscales together.
The validity, as assessed by convergent validity, was dem-
onstrated by the association between SF-12 and DASH.
Our study also has limitations. A major limitation is the
absence of outcomes data on about one-third of our pa-
tients. However, we believe this is an acceptable non-response
rate; moreover, anecdotally, we believe that patients who do
well are more likely to ignore our mailings, while patients who
were dissatisfied with their outcomes were more likely to
maintain communication with us. Therefore, we believe our
results are more weighed more so by negative reports than by
positive reports, and so the true results may in fact be better
than what we report here. Another potential limitation is
that this is a single-institutional study; and as an aca-
demic referral center, our patient population may be
different from other practices. For example, although the
literature indicates that venous patients present within
days of the thrombosis, our practice usually sees these
patients after weeks to months of conservative manage-
ment (ie, anticoagulation). Nevertheless, the volume of
TOS patients in our hospital is among the highest in the
nation, as demonstrated by comparison of our volume to
national database review, and so we believe our data are still
valuable.18 Also, as we only employed the transaxillary
surgical approach, we do not know the comparative effec-
tiveness of the supraclavicular surgical approach that is
commonly performed throughout the country. Addition-
ally, our study may be limited by the selection of SF-12
instead of SF-36. However, this choice was based on the
consideration that the SF survey was meant to be an ad-
junctive measure for our study, and so we believe the
benefit from reducing the survey burden outweighs any loss
in information value. Our study may also be limited by
the selection of DASH as the functional outcome measure.
We agree that some questions on the DASH may not beapplicable to TOS patients, and there may be other, more
appropriate questions to assess functional deficits seen in
these patients. We plan to further analyze our data in the
future to develop a modified DASH instrument that would
be more appropriate for TOS patients.
We conclude that neurogenic TOS patients who are
refractory to physical therapy and venous TOS patients
present with significant physical disability. Their quality of
life profile in general is similar to patients with chronic heart
failure, and, more specifically, in relation to upper extremity
functions, similar to patients with chronic rotator cuff tears.
Following first-rib resection, venous TOS patients typically
improved both physical and mental scores in shorter peri-
ods of time than their neurogenic counterparts. Addition-
ally, neurogenic and venous TOS patients returned to
full-time work/activity within the same length of time
postoperatively; however, neurogenic patients required
more secondary interventions in order to do that. We
further conclude that, in appropriately selected patients
with either neurogenic or venous TOS, surgical interven-
tion can improve their quality of life over time.
We wish to acknowledge Gina Forte for her assistance
in designing the Optical Mark Reader forms.
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Dr Ronald Fairman (Philadelphia, Pa). Does this type of
analysis assist you in terms of decision-making preoperatively? For
example, does it help you decide who might benefit from neuro-
genic thoracic outlet intervention?
Dr Rotellini-Coltvet. The scattergrams are not very wide at
the preoperative point, noting that the patients appear to be about
the same at baseline. However, what we did find postoperatively
and via a chart review was an ability to appropriately identify and
select patients preoperatively.
Preoperative components in selected appropriate neurogenic
patients include the following: knowing the patient for a long
period of time (around 2 years), confirm that the patient has
completed the physical therapy protocol, rule out C-spine disease
with a C-spine magnetic resonance imaging (MRI) scan, deter-
mine if pain management and/or pain medications are adequate in
controlling the pain, patient has a positive diagnostic lidocaine
block to confirm if surgical intervention will be successful, and
possesses motivation to return to work or their hobby.
A red flag for us is if they e-mail or call us more than three
times in 1 week. If this occurs, we bring the patient in for a
follow-up and implement a “tough love” stance.
Dr Freischlag. Really, we looked at whether or not the survey
could predict outcome, and because they all looked similar on
baseline, we haven’t been able to do that. We hope, as we follow
along, to be able to predict that, but for right now we haven’t been
able to use this survey as a prediction of success.
Dr Herbert Machleder (Los Angeles, Calif). Dr Freischlag
and her team, first at UCLA and then at Johns Hopkins, have made
major contributions to the literature and to our understanding of
TOS, and this is another beautifully presented paper.
I had one concern about the methodology. In the 38 ques-
tions on the DASH, developed as it was for primarily musculoskel-
etal problems, there is one question about dysesthesias, but there
are none about vascular symptoms; venous or arterial. This gives
rise to a problem called the “ceiling effect.” Where there are
insufficient questions in the domain of the disorder that you’re
examining, the patient really can’t reflect improvement on theIn the only other published paper that used the DASH to
assess surgical treatment of Paget-Schroetter Syndrome, the sur-
geons found that there was no difference in the DASH score
postoperatively, even though their surgical results were excellent.
They had achieved a normal hemodynamic status and there were
no episodes of re-thrombosis.
Could you refine the test so that it better addresses the
particular disability of the vascular TOS patient, before the test is
more widely disseminated and more widely used to evaluate TOS
treatment? As it is now presented in both papers, Paget-Schroetter
patients seem to have less initial disability and consequently less
improvement postoperatively. But, I think this may be an under-
estimation, there not being any questions about cyanosis, edema,
re-thrombosis, and venous “claudication”, etc.
Dr Rotellini-Coltvet. This was one of the concerns with
using the DASH as a solo instrument, that’s why the SF-12 was
added as a complementary measurement as it does look at overall
health status.
Dr Freischlag. I think we’re going to look at whether or not
we should use the DASH instrument. We did see improvement
with that and it did seem to match to the SF-12.
Dr Robert Thompson (St. Louis, Mo). One of the concerns I
had with the data you showed is that there was an overall retention
or response rate of 48% of all the patients that you initially enrolled
or operated on. Can you give us some insight into what the reasons
were that you only retained 48%, because this is otherwise a highly
devoted group of patients that you follow closely. Have you had a
chance to go back and look at entry criteria or data from the
patients that did not continue on and complete the entire survey
process? Were they in any way different than those who did
complete the survey? Could the data be skewed in any way by the
48% who did respond?
Dr Rotellini-Coltvet. It’s interesting because when we re-
viewed the charts, we found that the patients who were complain-
ing more were the ones completing the surveys. They were the
patients that we were seeing more of in the clinic. When patients
did well, we didn’t see or hear from them as much – they were too
busy enjoying life again. So for the most part, I think our data
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completed surveys from the patients who were doing well.
I think it would be helpful and beneficial if we could create a
web-based survey. We have many patients that live internationally
and travel across the country to see us that we lose patients purely
based on distance. Additionally, creating a shorter survey may also
increase response rates.
Dr Karl Illig (Rochester, NY). This is a very critical avenue
of exploration. As everybody who treats TOS knows, it’s a real
syndrome, but it’s very fuzzy. Most of the fuzziness arises from
the fact that we have no objective tests available for diagnosis.
While your data don’t strictly help us with diagnosis, I believe
that this sort of investigation is critical in that it starts to put us
on a little firmer quantitative platform. Rob Thompson, Julie
Freischlag, and a few others are forging ahead with a National
Institute of Health (NIH) proposal to help put some 21st
century science behind this diagnosis, so keep your eyes out for
efforts in this arena.
I am most interested in the scattergrams in the program book.
It looks like patients with neurogenic thoracic outlet seem to
continue to improve over the years, whereas those with venous
problems seem to improve more rapidly but then level off. Can you
give us any more insights from the shapes of your curves or from
your other observations?
You’re obviously accepting DASH and SF-12 as the best
instruments for this sort of evaluation we have at the present.
Do you have any plans to go further and perhaps create some-
thing a little more specific for thoracic outlet syndrome? In
other words, can you use your experience so far to work on an
outcomes evaluation instrument that is actually specific for this
disease entity?
Dr Rotellini-Coltvet. It’s been very rewarding working with
Dr Freischlag and over the course of the past 2 years I have seen our
practice change to better care for our patients. For example,
looking at the neurogenic TOS patients in particular, over time we
have been getting better at identifying recurrent symptoms faster
and implementing more aggressive therapy sooner. Therefore, it
would make sense why we are seeing improvement following lapses
at 24 months.
Dr Freischlag. Well, actually Dr Chang, who is sitting in the
front row also, works with us and helped us devise these instru-
ments. And that’s going to be one of his plans is to get a more
specific survey that we can then validate and then utilize as we go
forward. Even though these tools were good, and they did show
improvement, but it would be nice to be able to predict outcomes,
like you all want us to do. We do this survey, you look at it, you go,
okay, this one is going to do really well with the operation. And
that would be one contribution we can make.
We weren’t quite sure we were going to show anybody was
getting better. When you do this practice after many years, you
wonder if you’re helping anybody. And actually that was nice to see
those results, that’s why we sent in the abstract. You probably
wouldn’t have seen it if no one got better. But we did send that in
and we feel very confident that with the appropriately selected
ones, patients are getting better. And now we hope to maybe give
you an instrument to use so that you can select them too.
Dr Peter Gloviczki (Rochester, Minn). There is more and
more information in the literature that in venous thoracic outlet we
should do additional venous reconstruction in addition to decom-
pression of the thoracic outlet by resection of the first rib. And
that’s the practice that we are taking over at Mayo Clinic too.
And I’m wondering if you have any data, if the improvement
in the postoperative score is in any way related to patency of the
vein? Obviously we want to know if decompression alone is
enough as a first-stage operation or do we really have to do the
operations of Dr Molina, or what the St Louis group is proposing,
that we should do venous reconstruction at the same time.
Dr Freischlag. We actually have a paper that is in the process
of being published in Surgery that we presented at the Eastern
Vascular looking at our group of venous patients. And at Hopkinswe rarely get an acute thrombosed vein. We’ve only taken care of 3
or 4. We get our patients weeks to months to years later, which I’m
sure is your population too, with stenosis that we document by
duplex scan. And our treatment protocol has been to do the
first-rib resection scalenectomy and then do a venogram at 2
months and use balloon dilatation, which is required in about half
the patients.
We haven’t had to do venous bypasses or do patch angioplasty
because we do them transaxillary, which is different than some
other groups.
In this consortium, we are going to look at that to see whether
or not the supraclavicular approach with patch angioplasty that
some people are doing is superior. We’ve only lost a handful of
veins. We also treat chronically occluded ones too, which I
know you all know we have a series of about 15 that do open up
with anticoagulation postoperatively as well and we have a small
group of intermittent occlusion as well. But in the group that
was stenotic, I think we have one lost vein that just opened up
about 2 weeks ago on anticoagulation for 6 months. So yes,
they’re all open. And I think that also is probably the most
important thing that they won’t get better unless the vein is
open.
Dr Gloviczki. And just one follow-up question. You con-
cluded that in appropriately-selected patients this operation and
this technique works. Who are the appropriately-selected patients
in neurogenic Trans Atlantic Inter-Societal Consensus (TASC)?
Because I think nationwide, vascular surgeons operate less and less
neurogenic thoracic outlet syndrome. So could you tell us how do
you appropriately select the patients?
Dr Freischlag. Basically I think it’s an hour-long discussion
with patients that are highly motivated to get better. And we do
utilize the scalene block to help us determine which symptoms will
get better and what they will end up feeling like and what their
expectations are.
I actually think with neurogenic patients, you have to get the
expectations on the same page. So when you tell them what’s
going to get better, it has to do with the symptoms with their arm
and it’s not going to be their legs and their marriage and everything
else in their life. It’s just going to be that arm and that’s what’s
going to get better. And you’re going to have to work with me for
2 years to get there.
Lisa fields lots of telephone calls and lots of follow-up and
seeing them a lot over a period of time. They do like filling out the
study instrument.
The other thing is we have a great secretary named Nancy who
actually can screen them very well over the phone. And there are
many I never meet, because she tells me I don’t want to meet them.
And so I think similar to when a resident that you interview who
says something rude to your secretary, you never hire that resident
or fellow. It’s very similar. She can actually tell what’s going on
over the phone and knows whether we should see them or not, and
it helps Lisa and I out a lot.
So I think motivation, looking at what kind of pain manage-
ment they’re doing, what kind of opportunities they want to do in
the future. As you saw, about a third are disabled and you’re not
going to make them do something they weren’t doing, but you’ll
make them pain-free. We see them from all over. And having
partners all over the East Coast has been helpful, because in the
state of Pennsylvania this operation is not done by many people, so
we see all of them. And they’re far away from us, so we do need
help with that.
So I think it’s the gestalt. It’s 20 years of talking to them. It’s
Dr Machleder – who I really appreciate being here today. I sort of
brought him out of retirement to discuss this paper – teaching us
how to be able to look at these patients and having sympathy for
them. And not many people can do a big practice. We see probably
6 to 8 new patients a week now and operate on them every
Monday. So I think if you do have a big practice, you have many to
choose from.
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your patience with these patients that we find to be challenging.
My partner, Greg Landry, is doing functional outcome analy-
sis on patients with upper extremity procedures, including arterio-
venous access, to determine disability. And he has a very neatliving, such as putting a key in a lock and opening a doorknob and
dialing a phone, et cetera. Have you done any functional outcome
analysis or do you plan to do any for these patients?
Dr Freischlag. We have not, but it sounds like we need his
tool. Some of our questions do reflect functional outcome, but Ibattery of tests including activities performed for activities of daily think having a specific tool like that would be important.
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